The landscape of rheumatic and musculoskeletal disease research continues to evolve at pace, driven by scientific innovation, interdisciplinary collaboration and an increasing appreciation of the heterogeneity and complexity of the conditions we treat. As we welcome readers to touchREVIEWS in RMD Volume 5, Issue 1, we are reminded that progress in our field depends not only on advances in therapeutics, diagnostics and digital technologies, but also on the structures that support equitable access to care, early diagnosis and high-quality multidisciplinary practice.
In this issue, our authors highlight both enduring challenges and emerging opportunities across the breadth of rheumatic disease (RMD) care. Parihar and colleagues provide a compelling perspective on the development of specialized rare disease clinics, using myositis as a paradigm to illuminate the barriers that continue to impede optimal outcomes for patients with rare rheumatic diseases. Their article offers practical guidance for clinicians seeking to build sustainable referral networks, multidisciplinary teams and collaborative research environments, embodying incremental yet impactful advances in rare rheumatic diseases.
The importance of timely recognition in shaping long-term outcomes is underscored by Wong and Twilt, who revisit the often-challenging distinction between benign causes of musculoskeletal pain in childhood and the early manifestations of juvenile idiopathic arthritis. Their discussion is a salutary reminder that despite therapeutic advances, access barriers and the exclusion of paediatric populations from clinical trials remain critical obstacles to improving care for young people with chronic arthritis.
Digital therapeutics continue to expand the horizons of supportive care in rheumatology. A narrative review by Tsigarides et al. charts the rapid development of immersive virtual reality (VR) as a non-pharmacological modality capable of addressing pain, fatigue, fear of movement and other multidimensional symptoms across a range of chronic conditions. This comprehensive synthesis highlights the promise of personalized, accessible VR interventions while also calling for strengthened methodological rigour and clearer pathways to scalable clinical implementation.
Two articles in this issue turn our focus to interstitial lung disease (ILD), a major driver of morbidity and mortality in systemic autoimmune rheumatic diseases (SARDs). Lui et al. present real-world insights from a joint ILD clinic, offering valuable data on referral patterns, treatment strategies, outcomes and predictors of death or deterioration. Their findings reinforce the potential for effective therapeutic intervention in SARD-associated ILD, even in patients without overt autoimmune disease, and highlight the need for ongoing evaluation of outcomes and larger databases to support these results.
Finally, Mulvey et al. provide an overview of current approaches to screening, monitoring and treating ILD in SARDs. Their review articulates the challenges associated with the diagnosis, management and the development of targeted therapies for a condition defined by complex immunopathology and variable disease trajectories. The article highlights the need for disease-specific approaches in SARD-specific ILDs and underscores the importance of forthcoming guideline developments in standardizing care and addressing enduring unmet needs.
Together, the articles in this issue reflect the breadth of care in a specialty that is forward-looking, increasingly multidisciplinary and committed to improving the lived experiences and long-term outcomes of patients. They also embody the values that have guided my own tenure as Editor-in-Chief: scientific curiosity and learnings from clinical translation, clinical excellence and a collaborative ethos that welcomes perspectives from across the global rheumatology community.
Peter C Taylor
Peter C Taylor is Professor of Musculoskeletal Sciences at the University of Oxford and is a Fellow of St. Peter’s College. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for research on pathogenesis of arthritis. Professor Taylor has specialist clinical interests in inflammatory arthritis, development of novel therapies and the insights that targeted therapies provide into disease pathogenesis.
